|Awarded On||February 21, 2018|
|Title||Inhibiting Oxidative Phosphorylation: A Novel Strategy in Leukemia|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Marina Konopleva|
In adults, acute myeloid leukemia (AML) remains difficult to treat, and most patients are expected to die either of their disease or of treatment-related toxicities. The need for novel therapies is thus unquestioned. Cancer cells utilize glycolysis, mitochondrial respiration or both to convert the chemical energy of food molecules into cellular energy and biosynthetic building blocks. AML cells predominantly utilize mitochondrial respiration, and unlike normal cells, are deficient in glycolytic capacity. Oxidative phosphorylation (OxPhos) is a series of reactions within mitochondrial matrix, whereby energized electrons are transferred from the donor molecules and drive synthesis of ATP and...